Research
Metabolic adaptation
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is projected to increase from 33.7% (86.3 million people) in 2020 to 41.4% (121.9 million people) by 2050.
Health systems should prepare for a significant increase in MASLD cases.
StrongSupportsmedium confidence
The model predicted a steady increase in the prevalence of MASLD from 33.7% (86.3 million people) in 2020 to 41.4% (121.9 million people) by 2050.
Why this rating
Based on a decision analytical modeling study design.
Source
Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050
Phuc Le et al. · JAMA Network Open · 2025
DOI 10.1001/jamanetworkopen.2024.54707
other · n=2821624Cited 165×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Cases of metabolic dysfunction-associated steatohepatitis (MASH) are expected to rise from 14.9 million (5.8% of US adults) in 2020 to 23.2 million (7.9% of US adults) by 2050.Strong
- Liver-related mortality is estimated to increase from 30,500 deaths (1.0% of all-cause deaths in adults) in 2020 to 95,300 deaths (2.4%) in 2050.Strong
Related findings · Metabolic adaptation
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →